AM 720 KDWN
News, Traffic, Weather

US jury hits Takeda, Eli Lilly with $9 bln penalty

KDWN

TOKYO (AP) — A U.S. jury ordered Takeda Pharmaceutical Co. and Eli Lilly to pay $9 billion in punitive damages over a diabetes medicine linked to cancer, but Japan’s biggest drugmaker said Tuesday it will “vigorously challenge” the decision.

The U.S District Court in western Louisiana decided a $6 billion penalty for Takeda and $3 billion for its business partner and co-defendant Eli Lilly. It also ordered $1.5 million in compensatory damages in favor of the plaintiff.

The legal fight turned on whether Actos, which is a drug used to treat type-two diabetes, caused a patient’s bladder cancer and by implication was responsible for other cases of the cancer.

Takeda and Eli Lilly are facing numerous other lawsuits over the drug, which allege failure to warn about side effects and concealment of its health risks.

Kenneth Greisman, a general counsel at Takeda, said in a statement that the evidence does not support a link between Actos and bladder cancer.

“Takeda respectfully disagrees with the verdict, and we intend to vigorously challenge this outcome through all available legal means, including possible post-trial motions and an appeal,” he said.

Punitive damages are often reduced on appeal.

In June 2011, the U.S. Food and Drug Administration published a drug safety update on Actos, which said there was a 40 percent increase in bladder cancer risk in people who used the drug for longer than a year. It required that the cancer risk be added to the medication’s warning label. Actos has been sold since 1999.

Actos comes with warnings about various serious side effects, including liver problems and higher risk of broken bones.

A former Takeda medical reviewer, Helen Ge, alleged in a U.S. District Court filing in 2012 that the Japanese drugmaker understated the number of bladder cancer cases possibly linked to Actos in its disclosures to the FDA.

Shares of Osaka-based Takeda tanked on the Tokyo Stock Exchange, closing down 5.2 percent.

US jury hits Takeda, Eli Lilly with $9 bln penalty

KDWN

TOKYO (AP) — A U.S. jury ordered Takeda Pharmaceutical Co. and Eli Lilly to pay $9 billion in punitive damages over a diabetes medicine linked to cancer, but Japan’s biggest drugmaker said Tuesday it will “vigorously challenge” the decision.

The U.S District Court in western Louisiana decided a $6 billion penalty for Takeda and $3 billion for its business partner and co-defendant Eli Lilly. It also ordered $1.5 million in compensatory damages in favor of the plaintiff.

The legal fight turned on whether Actos, which is a drug used to treat type-two diabetes, caused a patient’s bladder cancer and by implication was responsible for other cases of the cancer.

Takeda and Eli Lilly are facing numerous other lawsuits over the drug, which allege failure to warn about side effects and concealment of its health risks.

Kenneth Greisman, a general counsel at Takeda, said in a statement that the evidence does not support a link between Actos and bladder cancer.

“Takeda respectfully disagrees with the verdict, and we intend to vigorously challenge this outcome through all available legal means, including possible post-trial motions and an appeal,” he said.

Punitive damages are often reduced on appeal.

In June 2011, the U.S. Food and Drug Administration published a drug safety update on Actos, which said there was a 40 percent increase in bladder cancer risk in people who used the drug for longer than a year. It required that the cancer risk be added to the medication’s warning label. Actos has been sold since 1999.

Actos comes with warnings about various serious side effects, including liver problems and higher risk of broken bones.

A former Takeda medical reviewer, Helen Ge, alleged in a U.S. District Court filing in 2012 that the Japanese drugmaker understated the number of bladder cancer cases possibly linked to Actos in its disclosures to the FDA.

Shares of Osaka-based Takeda tanked on the Tokyo Stock Exchange, closing down 5.2 percent.

US jury hits Takeda, Eli Lilly with $9 bln penalty

KDWN

TOKYO (AP) — A U.S. jury ordered Takeda Pharmaceutical Co. and Eli Lilly to pay $9 billion in punitive damages over a diabetes medicine linked to cancer, but Japan’s biggest drugmaker said Tuesday it will “vigorously challenge” the decision.

The District Court, Western District Louisiana, ordered a $6 billion penalty for Takeda and $3 billion for its business partner and co-defendant Eli Lilly. It also decided $1.5 million in compensatory damages in favor of the plaintiff.

The legal fight turned on whether Actos, which is a drug used to treat type-two diabetes, caused a patient’s bladder cancer and by implication was responsible for other cases of the cancer.

Kenneth Greisman, a general counsel at Takeda, said in a statement that the company disagrees with the verdict and that the evidence did not support the causal link between Actos and bladder cancer.

“Takeda respectfully disagrees with the verdict, and we intend to vigorously challenge this outcome through all available legal means, including possible post-trial motions and an appeal,” said Greisman.

Punitive damages are often reduced on appeal.

Greisman said he empathized with the plaintiff but the drug did not cause his cancer.

The drug comes with warnings about serious side effects, including liver problems, broken bones and higher risk of bladder cancer.

Osaka-based Takeda shares tanked on the Tokyo Stock Exchange, closing down 5.2 percent.

US jury hits Takeda, Eli Lilly with $9 bln penalty

KDWN

TOKYO (AP) — A U.S. jury ordered Takeda Pharmaceutical Co. and Eli Lilly to pay $9 billion in punitive damages over a diabetes medicine linked to cancer, but Japan’s biggest drugmaker said Tuesday it will “vigorously challenge” the decision.

The District Court, Western District Louisiana, ordered a $6 billion penalty for Takeda and $3 billion for its business partner and co-defendant Eli Lilly. It also decided $1.5 million in compensatory damages in favor of the plaintiff.

The legal fight turned on whether Actos, which is a drug used to treat type-two diabetes, caused a patient’s bladder cancer and by implication was responsible for other cases of the cancer.

Kenneth Greisman, a general counsel at Takeda, said in a statement that the company disagrees with the verdict and that the evidence did not support the causal link between Actos and bladder cancer.

“Takeda respectfully disagrees with the verdict, and we intend to vigorously challenge this outcome through all available legal means, including possible post-trial motions and an appeal,” said Greisman.

Punitive damages are often reduced on appeal.

Greisman said he empathized with the plaintiff but the drug did not cause his cancer.

The drug comes with warnings about serious side effects, including liver problems, broken bones and higher risk of bladder cancer.

Osaka-based Takeda shares tanked on the Tokyo Stock Exchange, closing down 5.2 percent.

US jury hits Takeda, Eli Lilly with $9 bln penalty

KDWN

TOKYO (AP) — A U.S. jury ordered Takeda Pharmaceuticals to pay $6 billion in punitive damages over a diabetes drug, but Japan’s biggest drug-maker is challenging the move.

The District Court, Western District Louisiana, on Tuesday also ordered a $3 billion penalty for co-defendant Eli Lilly, as well as $1.5 million in compensatory damages.

The legal fight was over Actos, a drug used to treat diabetes, as causing a patient’s bladder cancer.

Takeda Senior Vice President Kenneth Greisman said in a statement that Takeda disagrees with the verdict and plans post-trial motions and an appeal.

He said he empathized with the plaintiff but the drug did not cause his cancer.

The drug comes with warnings about serious side effects, including liver problems, broken bones and higher risk of bladder cancer.